Since identifying the cybersecurity incident on August 25, Boston Scientific has worked closely with CrowdStrike and other third-party cybersecurity experts to contain the threat, conduct a ...
Chronic pain is often misunderstood, underdiagnosed and undertreated. Today, new treatment options are helping more people find relief.
73.4% freedom from AF, AFL and atrial tachycardia (AT), which exceeded the performance goal of 40% or higher. A safety event rate of 2.4% and no reports of pulmonary vein stenosis, atrio-esophageal ...
Manufacturing, order fulfillment and shipping operations are now fully restored following the cybersecurity incident identified on August 25, 2026. Products are moving through our distribution network ...
NATICK, Mass., Oct. 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food ...
MARLBOROUGH, Mass., April 22, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported ...
"Penumbra is a well-established company with an experienced, high-performing team and this acquisition offers Boston Scientific an opportunity to enter new, fast-growing segments within the vascular ...
MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase ...
To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income ...
MARLBOROUGH, Mass., Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE: BTG) pursuant to the previously ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results